SRI-31255 is an orally active LRRK2 inhibitor with IC 50 values of 520 and 427 nM for human wild-type (WT) and mutant G2019S, respectively. SRI-31255 exerts neuroprotective effects by binding to the ATP-binding pocket of LRRK2 , inhibiting kinase activity. SRI-31255 can be used as a lead compound for the development of LRRK2-targeted drugs for the treatment of Parkinson's disease.
Products | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Autophagy | Products > Research Areas > Neurological Disease | Products > Signaling Pathways > LRRK2
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.